Jennifer Sobol, DO
Urology · West Bloomfield, MINPI 1558326926
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $28,067 of the $41,993 with a category attached, or 66.8%. AbbVie accounts for 74.4% of it on its own, with 32 other manufacturers making up the rest. Among urology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 492 payments — averaging $85.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$31K
- Medtronic$6K
- Axonics, Inc.$1K
- Coloplast$557
- Astellas Pharma US Inc$265
- Merck$218
- plus $2K from 27 others
Across 29 payments — averaging $2468.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$38K
- Ironwood Pharmaceuticals, Inc$20K
- GSK$13K
What the payments were for
- Speaking & faculty fees$28,06767%
- Travel & lodging$3,9379%
- Food & beverage$9,76923%
- Education$2191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 89 | $31,260 |
| Medtronic(2 entities) | 236 | $6,433 |
| Axonics, Inc. | 55 | $1,459 |
| Coloplast | 15 | $557 |
| Astellas Pharma US Inc | 12 | $265 |
| Merck | 8 | $218 |
| Sumitomo Pharma America, Inc. | 14 | $214 |
| Boston Scientific | 5 | $194 |
| Myriad Genetic Laboratories, Inc. | 2 | $128 |
| Pfizer | 1 | $125 |
| Bayer | 5 | $116 |
| Johnson & Johnson | 5 | $98 |
| Progenics Pharmaceuticals, Inc. | 4 | $94 |
| Olympus America Inc. | 4 | $86 |
| Urogen Pharma, Inc. | 4 | $83 |
| Forte Bio-pharma LLC | 5 | $81 |
| Avation Medical, Inc. | 3 | $75 |
| AstraZeneca | 3 | $72 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $60 |
| Dendreon Pharmaceuticals LLC | 2 | $47 |
| 180 Medical, Inc. | 3 | $46 |
| Angiodynamics, Inc. | 2 | $39 |
| Endo Pharmaceuticals Inc. | 2 | $38 |
| Ferring Pharmaceuticals Inc. | 2 | $35 |
| Sun Pharmaceutical Industries Inc. | 1 | $26 |
| Photocure Inc | 1 | $24 |
| Calyxo, Inc. | 1 | $22 |
| Blue Earth Diagnostics | 1 | $19 |
| Endo USA, Inc. | 1 | $19 |
| Teleflex LLC | 1 | $18 |
| Tolmar Pharmaceuticals, Inc. | 1 | $16 |
| Tolmar, Inc. | 1 | $15 |
| Therapeuticsmd, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,993 in reported general payments places this provider in the 95th percentile of 400 urology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 628 | $494,170 |
| GemtesaVibegron | 228 | $215,150 |
| Mirabegron ErMirabegron | 215 | $122,462 |
| Trospium Chloride ErTrospium Chloride | 317 | $69,479 |
| Methenamine Hippurate | 497 | $41,091 |
| Trimethoprim | 261 | $20,278 |
| Fosfomycin Tromethamine | 72 | $14,887 |
| Solifenacin Succinate | 271 | $13,390 |
| Estradiol | 137 | $12,323 |
| Tolterodine Tartrate ErTolterodine Tartrate | 78 | $9,641 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 301 | $7,159 |
| NitrofurantoinNitrofurantoin Macrocrystal | 149 | $5,788 |
| Tamsulosin Hcl | 262 | $5,733 |
| Trospium Chloride | 84 | $4,667 |
| Oxybutynin Chloride ErOxybutynin Chloride | 112 | $3,201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $265 | $494,170628 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $214 | $215,150228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 400 urology providers in Michigan.
Other urology in West Bloomfield
- Jason HafronWest Bloomfield$490K
- Gregory OldfordWest Bloomfield$28K
- Brian SeifmanWest Bloomfield$21K
- Ashok ReddySterling Heights$4.9M
- William RobertsAnn Arbor$973K
- Kenneth KernenTroy$910K
- William JohnstonLivonia$675K
- Khurshid GhaniAnn Arbor$413K
- Richard BennettRoyal Oak$361K
- Ryan NelsonUtica$296K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.